Neuralia TMS Proudly Announces TMS Therapy Solutions in Como

Australia, 10th Jul 2024 - Neuralia TMS is proud to announce the introduction of its cutting-edge Transcranial Magnetic Stimulation (TMS) therapy solutions in Como, designed to address depression and anxiety at their root neuraliatms.com.au. The company’s facility located at Unit 2A/125 Melville Parade, Marview House, Como WA 6152, is equipped to deliver this breakthrough treatment, which harnesses high-strength magnetic fields to stimulate neuroplasticity and promote increased neural connections in underactive brain regions.

TMS therapy, first developed in 1985 and approved by the FDA for the treatment of depression in 2008, has been recognised as a significant advancement in the treatment of mental health conditions. Since November 2021, it has been listed under Medicare for Treatment Resistant Depression, offering a new avenue of hope for individuals who have not responded to traditional treatments. This evidence-based therapy is supported by over 35 years of research, confirming its efficacy and safety.

Dr. Shanek Wick, spokesperson for Neuralia TMS, emphasises the importance of this development: "The introduction of TMS therapy at Neuralia TMS represents a significant milestone in mental health treatment in the Como area. TMS offers a non-invasive, drug-free option for individuals suffering from depression and anxiety, providing them with a new opportunity for recovery."

TMS therapy works by stimulating neural activity in specific brain regions that are typically underactive in individuals with mental health conditions. For instance, decreased activity in the prefrontal cortex is often observed in those with depression and anxiety. This area of the brain is crucial for mood regulation, and by enhancing its activity, TMS helps alleviate symptoms associated with these conditions. PET scans of individuals with and without depression vividly illustrate the differences in prefrontal cortex activity, underscoring the potential of TMS to address these disparities.

The treatment process is designed to be quick and convenient, fitting seamlessly into daily routines without the need for recovery time or hospital admissions. This makes TMS an attractive option for those seeking effective treatment without the disruptions often associated with other therapies.

Dr. Wick further elaborates on the future outlook of TMS therapy: "The ongoing advancements in TMS technology and its expanding applications in treating various mental health conditions are promising. Neuralia TMS is committed to staying at the forefront of these developments, ensuring that the patients have access to the latest and most effective treatments available."

In addition to treating depression and anxiety, TMS therapy shows potential for addressing other conditions such as chronic pain, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD). The continued research and development in this field are expected to broaden the scope of TMS applications, offering new hope for individuals suffering from a range of neurological and psychological conditions.

Neuralia TMS’s new facility in Como is poised to become a centre of excellence for TMS therapy, staffed by a team of dedicated professionals committed to delivering the highest standards of care. The team at Neuralia TMS is well-versed in the latest TMS protocols and techniques, ensuring that each patient receives personalised and effective treatment.

For more information about Neuralia TMS and its new TMS Como therapy solutions, please contact the company at 08 6230 3996 or via email at info@neuralia.com.au. 

Media Contact

Organization: Neuralia TMS Perth (Como)

Contact Person: Dr. Shanek Wick

Website: https://www.neuraliatms.com.au/

Email: info@neuralia.com.au

Contact Number: +61862303996

Address:Unit 2A/125 Melville Parade

Address 2: Marview House, Como WA 6152

Country:Australia

Release id:14065

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

---